Thomas V Riley

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3042309/publications.pdf

Version: 2024-02-01

162 papers	6,837 citations	81900 39 h-index	74163 75 g-index
169 all docs	169 docs citations	169 times ranked	6049 citing authors

#	Article	IF	Citations
1	Mechanism of Action of Melaleuca alternifolia (Tea Tree) Oil on Staphylococcus aureus Determined by Time-Kill, Lysis, Leakage, and Salt Tolerance Assays and Electron Microscopy. Antimicrobial Agents and Chemotherapy, 2002, 46, 1914-1920.	3.2	760
2	Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2014, 69, 881-891.	3.0	461
3	Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. Journal of Antimicrobial Chemotherapy, 2003, 51, 1339-1350.	3.0	268
4	Diversity and Evolution in the Genome of Clostridium difficile. Clinical Microbiology Reviews, 2015, 28, 721-741.	13.6	253
5	Evolutionary History of the Clostridium difficile Pathogenicity Locus. Genome Biology and Evolution, 2014, 6, 36-52.	2.5	190
6	Epidemiology of Clostridium difficile infection in Asia. Antimicrobial Resistance and Infection Control, 2013, 2, 21.	4.1	186
7	Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infectious Diseases, The, 2010, 10, 395-404.	9.1	178
8	Asymptomatic Clostridium difficile colonization: epidemiology and clinical implications. BMC Infectious Diseases, 2015, 15, 516.	2.9	159
9	Effects of Melaleuca alternifolia (Tea Tree) Essential Oil and the Major Monoterpene Component Terpinen-4-ol on the Development of Single- and Multistep Antibiotic Resistance and Antimicrobial Susceptibility. Antimicrobial Agents and Chemotherapy, 2012, 56, 909-915.	3.2	124
10	Comorbidities, Exposure to Medications, and the Risk of Community-Acquired Clostridium difficile Infection: A Systematic Review and Meta-analysis. Infection Control and Hospital Epidemiology, 2015, 36, 132-141.	1.8	123
11	Genome Analysis of Clostridium difficile PCR Ribotype 014 Lineage in Australian Pigs and Humans Reveals a Diverse Genetic Repertoire and Signatures of Long-Range Interspecies Transmission. Frontiers in Microbiology, 2016, 7, 2138.	3.5	117
12	Macro and Micro Diversity of Clostridium difficile Isolates from Diverse Sources and Geographical Locations. PLoS ONE, 2012, 7, e31559.	2.5	114
13	Emergence of a Ribotype 244 Strain of Clostridium difficile Associated With Severe Disease and Related to the Epidemic Ribotype 027 Strain. Clinical Infectious Diseases, 2014, 58, 1723-1730.	5.8	111
14	Increasing incidence of Clostridium difficile infection, Australia, 2011â€“2012. Medical Journal of Australia, 2014, 200, 272-276.	1.7	96
15	Clostridium difficile infection: Evolution, phylogeny and molecular epidemiology. Infection, Genetics and Evolution, 2017, 49, 1-11.	2.3	89
16	An environmental cleaning bundle and health-care-associated infections in hospitals (REACH): a multicentre, randomised trial. Lancet Infectious Diseases, The, 2019, 19, 410-418.	9.1	86
17	Epidemiology of Clostridium difficile in infants in Oxfordshire, UK: Risk factors for colonization and carriage, and genetic overlap with regional C. difficile infection strains. PLoS ONE, 2017, 12, e0182307.	2.5	82
18	Community-Acquired Clostridium difficile-Associated Diarrhea. Clinical Infectious Diseases, 1995, 20, S263-S265.	5.8	79

#	Article	IF	Citations
19	Phage Ï•C2 Mediates Transduction of Tn 6215 , Encoding Erythromycin Resistance, between Clostridium difficile Strains. MBio, 2013, 4, e00840-13.	4.1	79
20	Cross-Sectional Study Reveals High Prevalence of Clostridium difficile Non-PCR Ribotype 078 Strains in Australian Veal Calves at Slaughter. Applied and Environmental Microbiology, 2013, 79, 2630-2635.	3.1	79
21	Nationwide Surveillance Study of Clostridium difficile in Australian Neonatal Pigs Shows High Prevalence and Heterogeneity of PCR Ribotypes. Applied and Environmental Microbiology, 2015, 81, 119-123.	3.1	76
22	Evolutionary and Genomic Insights into Clostridioides difficile Sequence Type 11: a Diverse Zoonotic and Antimicrobial-Resistant Lineage of Global One Health Importance. MBio, 2019, 10, .	4.1	73
23	Clostridium difficileâ€“Associated Diarrhea: Epidemiological Data from Western Australia Associated with a Modified Antibiotic Policy. Clinical Infectious Diseases, 2002, 35, 1457-1462.	5.8	70
24	Increasing Prevalence of Toxin A-Negative, Toxin B-Positive Isolates of Clostridium difficile in Korea: Impact on Laboratory Diagnosis. Journal of Clinical Microbiology, 2008, 46, 1116-1117.	3.9	69
25	First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Medical Journal of Australia, 2009, 190, 706-708.	1.7	65
26	Genomic Delineation of Zoonotic Origins of Clostridium difficile. Frontiers in Public Health, 2019, 7, 164.	2.7	61
27	Clostridium difficile ribotype 017 â€“ characterization, evolution and epidemiology of the dominant strain in Asia. Emerging Microbes and Infections, 2019, 8, 796-807.	6.5	61
28	Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review. Infectious Diseases and Therapy, 2016, 5, 231-251.	4.0	59
29	Effect of phage infection on toxin production by Clostridium difficile. Journal of Medical Microbiology, 2005, 54, 129-135.	1.8	58
30	New types of toxin A-negative, toxin B-positive strains among clinical isolates of Clostridium difficile in Australia. Journal of Medical Microbiology, 2011, 60, 1108-1111.	1.8	54
31	Extended spectrum cephalosporins and Clostridium difficile. Journal of Antimicrobial Chemotherapy, 1989, 23, 929-931.	3.0	52
32	Major genetic discontinuity and novel toxigenic species in Clostridioides difficile taxonomy. ELife, 2021, 10, .	6.0	50
33	Surveillance for antimicrobial resistance in Australian isolates ofClostridium difficile, 2013â€“14. Journal of Antimicrobial Chemotherapy, 2015, 70, 2992-2999.	3.0	49
34	Severe infection with Clostridium difficile PCR ribotype 027 acquired in Melbourne, Australia. Medical Journal of Australia, 2011, 194, 369-371.	1.7	47
35	Clostridioides difficile infection in the Asia-Pacific region. Emerging Microbes and Infections, 2020, 9, 42-52.	6.5	47
36	High prevalence of toxigenic Clostridium difficile in public space lawns in Western Australia. Scientific Reports, 2017, 7, 41196.	3.3	46

#	Article	IF	Citations
37	Diarrheal disease due to Clostridium difficile in general practice. Pathology, 1991, 23, 346-349.	0.6	45
38	Non-radioactive restriction fragment length polymorphism (RFLP) typing ofClostridium difficile. FEMS Microbiology Letters, 1991, 79, 269-272.	1.8	43
39	The changes of PCR ribotype and antimicrobial resistance of Clostridium difficile in a tertiary care hospital over 10 years. Journal of Medical Microbiology, 2014, 63, 819-823.	1.8	43
40	Clostridium difficile Infection in Production Animals and Avian Species: A Review. Foodborne Pathogens and Disease, 2016, 13, 647-655.	1.8	43
41	Adaptation of host transmission cycle during Clostridium difficile speciation. Nature Genetics, 2019, 51, 1315-1320.	21.4	41
42	The Epidemiology of Clostridium difficile Infection in Japan: A Systematic Review. Infectious Diseases and Therapy, 2018, 7, 39-70.	4.0	40
43	Prevalence of Gastrointestinal Clostridium difficile Carriage in Australian Sheep and Lambs. Applied and Environmental Microbiology, 2013, 79, 5689-5692.	3.1	39
44	Novel Molecular Type ofClostridium difficilein Neonatal Pigs, Western Australia. Emerging Infectious Diseases, 2013, 19, 790-2.	4.3	39
45	Clostridium difficile Infection in Humans and Piglets: A â€˜One Healthâ€™ Opportunity. Current Topics in Microbiology and Immunology, 2012, 365, 299-314.	1.1	38
46	Mechanisms of hypervirulent Clostridium difficile ribotype 027 displacement of endemic strains: an epidemiological model. Scientific Reports, 2015, 5, 12666.	3.3	38
47	Respiratory tract infections due toBranhamella catarrhalis: epidemiological data from Western Australia. Epidemiology and Infection, 1987, 99, 445-453.	2.1	37
48	Clostridium difficile Infection Seasonality: Patterns across Hemispheres and Continents â€“ A Systematic Review. PLoS ONE, 2015, 10, e0120730.	2.5	37
49	Clostridium difficile in horses in Australia â€“ a preliminary study. Journal of Medical Microbiology, 2011, 60, 1188-1192.	1.8	36
50	Infection with Toxin A-Negative, Toxin B-Negative, Binary Toxin-Positive Clostridium difficile in a Young Patient with Ulcerative Colitis. Journal of Clinical Microbiology, 2015, 53, 3702-3704.	3.9	36
51	Clostridium difficile exposure as an insidious source of infection in healthcare settings: an epidemiological model. BMC Infectious Diseases, 2013, 13, 376.	2.9	35
52	Antimicrobial resistance in Clostridioides difficile. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 2459-2478.	2.9	35
53	Bacteremia with a large clostridial toxin-negative, binary toxin-positive strain of Clostridium difficile. Anaerobe, 2009, 15, 249-251.	2.1	34
54	The Complexity and Diversity of the Pathogenicity Locus in Clostridium difficile Clade 5. Genome Biology and Evolution, 2014, 6, 3159-3170.	2.5	31

#	Article	IF	Citations
55	Clostridium difficile laboratory testing in Australia and New Zealand: national survey results and Australasian Society for Infectious Diseases recommendations for best practice. Pathology, 2011, 43, 482-487.	0.6	30
56	Incorrect diagnosis of Clostridium difficile infection in a university hospital in Japan. Journal of Infection and Chemotherapy, 2015, 21, 718-722.	1.7	30
57	Synthesis and antimicrobial activity of binaphthyl-based, functionalized oxazole and thiazole peptidomimetics. Organic and Biomolecular Chemistry, 2015, 13, 10813-10824.	2.8	30
58	Binaphthyl-1,2,3-triazole peptidomimetics with activity against Clostridium difficile and other pathogenic bacteria. Organic and Biomolecular Chemistry, 2015, 13, 5743-5756.	2.8	29
59	Clostridium difficile clade 5 in Australia: antimicrobial susceptibility profiling of PCR ribotypes of human and animal origin. Journal of Antimicrobial Chemotherapy, 2016, 71, 2213-2217.	3.0	29
60	Changes in knowledge and attitudes of hospital environmental services staff: The Researching Effective Approaches to Cleaning in Hospitals (REACH) study. American Journal of Infection Control, 2018, 46, 980-985.	2.3	29
61	Researching effective approaches to cleaning in hospitals: protocol of the REACH study, a multi-site stepped-wedge randomised trial. Implementation Science, 2015, 11, 44.	6.9	28
62	Antimicrobial resistance in Clostridium difficile ribotype 017. Expert Review of Anti-Infective Therapy, 2020, 18, 17-25.	4.4	28
63	Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles: synthesis, antibacterial evaluation and preliminary mechanism of action studies. European Journal of Medicinal Chemistry, 2019, 168, 386-404.	5.5	27
64	Antibiotics and healthcare facility-associatedClostridioides difficileinfection: systematic review and meta-analysis 2020 update. Journal of Antimicrobial Chemotherapy, 2021, 76, 1676-1688.	3.0	27
65	The antimicrobial activity of tea tree oil. Medical Journal of Australia, 1994, 160, 236-236.	1.7	26
66	Nosocomial diarrhoea due to Clostridium difficile. Current Opinion in Infectious Diseases, 2004, 17, 323-327.	3.1	26
67	Prevalence of Clostridium difficile colonization among healthcare workers. BMC Infectious Diseases, 2013, 13, 459.	2.9	26
68	A Phenotypically Silent vanB2 Operon Carried on a Tn 1549 -Like Element in Clostridium difficile. MSphere, 2016, 1, .	2.9	26
69	Susceptibility of Clostridium difficile to the food preservatives sodium nitrite, sodium nitrate and sodium metabisulphite. Anaerobe, 2016, 37, 67-71.	2.1	26
70	Antimicrobial Susceptibilities of Clostridium difficile Isolates from 12 Asia-Pacific Countries in 2014 and 2015. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	26
71	Staphylococcus saprophyticus urinary tract infections: epidemiological data from Western Australia. European Journal of Epidemiology, 1996, 12, 51-54.	5.7	25
72	Isolation of Clostridium difficile from faecal specimens â€“ a comparison of chromID C. difficile agar and cycloserine-cefoxitin-fructose agar. Journal of Medical Microbiology, 2013, 62, 1423-1427.	1.8	25

#	Article	IF	Citations
73	Antimicrobial susceptibility of Clostridium difficile isolated in Thailand. Antimicrobial Resistance and Infection Control, 2017, 6, 58.	4.1	25
74	Laboratory Detection of Clostridium difficile in Piglets in Australia. Journal of Clinical Microbiology, 2014, 52, 3856-3862.	3.9	24
75	Laboratory-based surveillance of Clostridium difficile strains circulating in the Australian healthcare setting in 2012. Pathology, 2017, 49, 309-313.	0.6	24
76	High Prevalence of Toxigenic and Nontoxigenic Clostridium difficile Strains in Malaysia. Journal of Clinical Microbiology, 2018, 56, .	3.9	24
77	Inspiration from Old Dyes: Tris(stilbene) Compounds as Potent Gramâ€Positive Antibacterial Agents. Chemistry - A European Journal, 2013, 19, 17980-17988.	3.3	23
78	Assessing control bundles for Clostridium difficile : a review and mathematical model. Emerging Microbes and Infections, 2014, 3, 1-8.	6.5	23
79	Molecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in Thailand. PLoS ONE, 2015, 10, e0127026.	2.5	23
80	Comparison of Clostridium difficile Ribotypes Circulating in Australian Hospitals and Communities. Journal of Clinical Microbiology, 2017, 55, 216-225.	3.9	23
81	Clostridium difficile Infections amongst Patients with Haematological Malignancies: A Data Linkage Study. PLoS ONE, 2016, 11, e0157839.	2.5	22
82	Community-associated Clostridium difficile infection in emergency department patients in Western Australia. Anaerobe, 2017, 48, 121-125.	2.1	22
83	Antimicrobial susceptibility of Clostridium difficile isolated from food and environmental sources in Western Australia. International Journal of Antimicrobial Agents, 2018, 52, 411-415.	2.5	22
84	Antibiotic-Associated Diarrhoea. Pharmacoeconomics, 1996, 10, 1-3.	3.3	21
85	A population-based spatio-temporal analysis of Clostridium difficile infection in Queensland, Australia over a 10-year period. Journal of Infection, 2014, 69, 447-455.	3.3	21
86	Molecular methods for detecting and typing of Clostridium difficile. Pathology, 2015, 47, 211-218.	0.6	21
87	Evaluation of selective media for the isolation of Brachyspira aalborgi from human faeces. Journal of Medical Microbiology, 2003, 52, 509-513.	1.8	20
88	Epidemic Clostridium difficile. Medical Journal of Australia, 2006, 185, 133-134.	1.7	20
89	Evaluation of the BD Max Cdiff assay for the detection of toxigenic Clostridium difficile in human stool specimens. Pathology, 2015, 47, 165-168.	0.6	20
90	Laboratory-based surveillance of Clostridium difficile circulating in Australia, September â€“ November 2010. Pathology, 2016, 48, 257-260.	0.6	20

#	Article	IF	Citations
91	Burden of Clostridium difficile infection: Associated hospitalization in a cohort of middle-aged and older adults. American Journal of Infection Control, 2017, 45, 508-511.	2.3	20
92	Persistence of Clostridium difficile RT 237 infection in a Western Australian piggery. Anaerobe, 2016, 37, 62-66.	2.1	19
93	Diverse bacterial species contribute to antibiotic-associated diarrhoea and gastrointestinal damage. Journal of Infection, 2018, 77, 417-426.	3.3	19
94	High prevalence and diversity of tcdA-negative and tcdB-positive, and non-toxigenic, Clostridium difficile in Thailand. Anaerobe, 2019, 57, 4-10.	2.1	19
95	Clostridium difficile infection in Thailand. International Journal of Antimicrobial Agents, 2015, 45, 1-7.	2.5	17
96	Evaluation of the Cepheid Xpert C. difficile/Epiand Meridian Bioscienceillumigene C. difficile Assays for Detecting Clostridium difficile Ribotype 033 Strains. Journal of Clinical Microbiology, 2015, 53, 973-975.	3.9	17
97	Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region. Emerging Microbes and Infections, 2019, 8, 1553-1562.	6.5	17
98	Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an inÂvivo C. difficile infection model. European Journal of Medicinal Chemistry, 2019, 170, 203-224.	5.5	17
99	Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Scientific Reports, 2018, 8, 15735.	3.3	16
100	Laboratory-Based Surveillance of Clostridium difficile Infection in Australian Health Care and Community Settings, 2013 to 2018. Journal of Clinical Microbiology, 2020, 58, .	3.9	16
101	Genomic basis of antimicrobial resistance in non-toxigenic Clostridium difficile in Southeast Asia. Anaerobe, 2020, 66, 102290.	2.1	16
102	25â€Hydroxyvitamin D Concentrations and Clostridium difficile Infection: A Metaâ€Analysis. Journal of Parenteral and Enteral Nutrition, 2017, 41, 890-895.	2.6	15
103	Is Clostridium difficile a threat to Australia's biosecurity?. Medical Journal of Australia, 2009, 190, 661-662.	1.7	14
104	Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection. Anaerobe, 2018, 49, 103-111.	2.1	14
105	High prevalence of Clostridium difficile in soil, mulch and lawn samples from the grounds of Western Australian hospitals. Anaerobe, 2019, 60, 102065.	2.1	14
106	A series of three cases of severe Clostridium difficile infection in Australia associated with a binary toxin producing clade 2 ribotype 251 strain. Anaerobe, 2019, 55, 117-123.	2.1	14
107	High Prevalence of Clostridium difficile in Home Gardens in Western Australia. Applied and Environmental Microbiology, 2020, 87, .	3.1	14
108	Antimicrobial resistance surveillance of Clostridioides difficile in Australia, 2015â€“18. Journal of Antimicrobial Chemotherapy, 2021, 76, 1815-1821.	3.0	14

#	Article	IF	Citations
109	â€œNaturalâ€•therapy for infectious diseases. Medical Journal of Australia, 1996, 164, 94-95.	1.7	13
110	Comparison of ChromID C. difficile agar and cycloserine-cefoxitin-fructose agar for the recovery of Clostridium difficile. Pathology, 2013, 45, 495-500.	0.6	13
111	Clostridium difficileâ€"Diagnostic and Clinical Challenges. Clinical Chemistry, 2016, 62, 310-314.	3.2	13
112	Clostridium difficile in soil conditioners, mulches and garden mixes with evidence of a clonal relationship with historical food and clinical isolates. Environmental Microbiology Reports, 2020, 12, 672-680.	2.4	13
113	Molecular Characterization of, and Antimicrobial Resistance in, Clostridioides difficile from Thailand, 2017â€"2018. Microbial Drug Resistance, 2021, 27, 1505-1512.	2.0	13
114	Whole-genome sequencing links Clostridium (Clostridioides) difficile in a single hospital to diverse environmental sources in the community. Journal of Applied Microbiology, 2022, 133, 1156-1168.	3.1	13
115	The Synthesis of Fluorescent DNA Intercalator Precursors through Efficient Multiple Heck Reactions. Australian Journal of Chemistry, 2011, 64, 316.	0.9	12
116	Routine detection of Clostridium difficile in Western Australia. Anaerobe, 2016, 37, 34-37.	2.1	12
117	1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium. Journal of Antimicrobial Chemotherapy, 2018, 73, 1562-1569.	3.0	12
118	Spectrum of antibacterial activity and mode of action of a novel tris-stilbene bacteriostatic compound. Scientific Reports, 2018, 8, 6912.	3.3	12
119	Clostridium difficile in Asia: Opportunities for One Health Management. Tropical Medicine and Infectious Disease, 2019, 4, 7.	2.3	12
120	Prevalence of binary toxin positive Clostridium difficile in diarrhoeal humans in the absence of epidemic ribotype 027. PLoS ONE, 2017, 12, e0187658.	2.5	11
121	Antimicrobial resistance in large clostridial toxin-negative, binary toxin-positive Clostridium difficile ribotypes. Anaerobe, 2018, 54, 55-60.	2.1	11
122	Synthesis of Mono and Bis[60]fullereneâ€Based Dicationic Peptoids. European Journal of Organic Chemistry, 2015, 2015, 195-201.	2.4	10
123	Severe Clostridium difficile infection in New Zealand associated with an emerging strain, PCR-ribotype 244. New Zealand Medical Journal, 2013, 126, 9-14.	0.5	10
124	Phenotypic characterisation of Clostridium difficile PCR ribotype 251, an emerging multi-locus sequence type clade 2 strain in Australia. Anaerobe, 2019, 60, 102066.	2.1	9
125	Evaluation of blood culture systems for detection of the intestinal spirochaete Brachyspira (Serpulina) pilosicoli in human blood. Journal of Medical Microbiology, 2000, 49, 1031-1036.	1.8	9
126	Legionella longbeachae in Western Australian potting mix. Medical Journal of Australia, 1997, 166, 387-387.	1.7	8

#	Article	IF	Citations
127	Molecular characterization and antimicrobial susceptibilities of Clostridium difficile clinical isolates from Victoria, Australia. Anaerobe, 2015, 34, 80-83.	2.1	8
128	Clostridium difficile infection in the Lao Peopleâ€™s Democratic Republic: first isolation and review of the literature. BMC Infectious Diseases, 2017, 17, 635.	2.9	8
129	Clostridium difficile Guidelines. Clinical Infectious Diseases, 2018, 67, 1639.	5.8	8
130	Mild or Malign: Clinical Characteristics and Outcomes of Clostridium difficile Infection in Thailand. Journal of Clinical Microbiology, 2020, 58, .	3.9	8
131	A species-wide genetic atlas of antimicrobial resistance in Clostridioides difficile. Microbial Genomics, 2021, 7, .	2.0	8
132	Molecular Epidemiology of Clostridioides difficile Infections in Children. Journal of the Pediatric Infectious Diseases Society, 2021, 10, S34-S40.	1.3	7
133	Positional Isomers of Biphenyl Antimicrobial Peptidomimetic Amphiphiles. ACS Medicinal Chemistry Letters, 2021, 12, 413-419.	2.8	7
134	Two cases of Clostridium difficile infection in unrelated oncology patients attributable to a single clone of C. difficile PCR ribotype 126. JMM Case Reports, 2015, 2, .	1.3	7
135	Genetically related Clostridium difficile from water sources and human <scp>CDI</scp> cases revealed by wholeâ€genome sequencing. Environmental Microbiology, 2022, 24, 1221-1230.	3.8	7
136	Clostridioides difficile infection and One Health: an equine perspective. Environmental Microbiology, 2022, 24, 985-997.	3.8	7
137	Clostridioides difficile infection in Africa: A narrative review. Anaerobe, 2022, 74, 102549.	2.1	7
138	Penicillin resistance in laboratory isolates of Streptococcus pneumoniae, in Western Australia, 1990-1994. European Journal of Epidemiology, 1998, 14, 611-615.	5.7	6
139	Community-AcquiredClostridium difficileInfection, Queensland, Australia. Emerging Infectious Diseases, 2016, 22, 1659-1661.	4.3	6
140	Aboriginal and non-Aboriginal children in Western Australia carry different serotypes of pneumococci with different antimicrobial susceptibility profiles. Pneumonia (Nathan Qld), 2016, 8, 15.	6.1	6
141	Community-acquired Clostridium difficile infection and Australian food animals. Microbiology Australia, 2015, 36, 111.	0.4	6
142	Human Clostridium difficile infection caused by a livestock-associated PCR ribotype 237 strain in Western Australia. JMM Case Reports, 2016, 3, e005062.	1.3	6
143	Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile. Letters in Applied Microbiology, 2022, 75, 526-536.	2.2	6
144	Surveillance snapshot of Clostridium difficile infection in hospitals across Queensland detects binary toxin producing ribotype UK 244. Communicable Diseases Intelligence, 2014, 38, E279-84.	0.5	6

#	Article	IF	Citations
145	Molecular epidemiology of Clostridium difficile isolated from piglets. Veterinary Microbiology, 2019, 237, 108408.	1.9	5
146	One Health: the global challenge of Clostridium difficile infection. Microbiology Australia, 2020, 41, 23.	0.4	5
147	Cationic Peptidomimetic Amphiphiles Having a N-Aryl- or N-Naphthyl-1,2,3-Triazole Core Structure Targeting Clostridioides (Clostridium) difficile: Synthesis, Antibacterial Evaluation, and an In Vivo C. difficile Infection Model. Antibiotics, 2021, 10, 913.	3.7	5
148	Esculin hydrolysis negative and TcdA-only producing strains of Clostridium (Clostridioides) difficile from the environment in Western Australia. Journal of Applied Microbiology, 2022, 133, 1183-1196.	3.1	5
149	Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile. Journal of Antimicrobial Chemotherapy, 2021, 76, 967-972.	3.0	4
150	Clostridioides (Clostridium) difficile in children with diarrhoea in Vietnam. Anaerobe, 2022, , 102550.	2.1	4
151	Global evolutionary dynamics and resistome analysis of Clostridioides difficile ribotype 017. Microbial Genomics, 2022, 8, .	2.0	4
152	Evaluation of the Cepheid Â® Xpert Â® C.Âdifficile binary toxin (BT) diagnostic assay. Anaerobe, 2018, 51, 12-16.	2.1	3
153	Linkage study of surveillance and hospital admission data to investigate Clostridium difficile infection in hospital patients in Perth, Western Australia. Anaerobe, 2022, 74, 102528.	2.1	3
154	Development of 1,2,4-Oxadiazole Antimicrobial Agents to Treat Enteric Pathogens within the Gastrointestinal Tract. ACS Omega, 2022, 7, 6737-6759.	3.5	3
155	Comparison of the Vidas C.Âdifficile and Quik Chek-60 glutamate dehydrogenase assays for the detection of Clostridium difficile in faecal samples. Pathology, 2016, 48, 506-508.	0.6	2
156	Clostridium difficile infection: the next big thing!. Microbiology Australia, 2012, 33, 163.	0.4	2
157	Clostridioides (Clostridium) difficile isolated from paediatric patients in Western Australia 2019â€“2020. Pathology, 2022, , .	0.6	2
158	Microbiological evaluation of the ability of the DEKO-190 Washer/Disinfector to remove Clostridium difficile spores from bedpan surfaces. Infection, Disease and Health, 2019, 24, 208-211.	1.1	1
159	Can sequencing improve the diagnosis and management of Clostridioides difficile infection?. Expert Review of Molecular Diagnostics, 2021, 21, 429-431.	3.1	1
160	Complete Genome Assemblies of Three Highly Prevalent, Toxigenic Clostridioides difficile Strains Causing Health Care-Associated Infections in Australia. Microbiology Resource Announcements, 2021, 10, e0059921.	0.6	1
161	The impact of antimicrobial resistance on induction, transmission and treatment of Clostridium difficile infection. Microbiology Australia, 2019, 40, 77.	0.4	1
162	Antimicrobial-resistant Bacteroides fragilis in Thailand and their inhibitory effect inÂvitro on the growth of Clostridioides difficile. Anaerobe, 2022, 73, 102505.	2.1	1